Data protection Impressum

Life sciences

HeroSupport and Calico Biosystems join Tech4Eva, a six-month equity-free accelerator dedicated to advancing women’s health technologies globally.

HeroSupport and Calico Biosystems selected for the Tech4Eva accelerator program

15 May 2024

ORamaVR is set to enhance its innovative VR solutions for medical training with new support from Innosuisse's Scale-up Coaching program.

ORamaVR receives Scale-up Award from Innosuisse to accelerate growth

15 May 2024

Takeda will receive an exclusive option to license AC Immune's ACI-24.060, a breakthrough therapy to combat the progression of Alzheimer's disease, for an upfront payment of USD 100 million and potential milestone payments of USD 2.1 billion.

AC Immune and Takeda sign USD 100 million deal to treat Alzheimer’s disease

13 May 2024

Ikerian AG, along with its subsidiary RetinAI, has successfully completed a USD 6.18 million Series A extension financing round to propel the development and commercial rollout of innovative medical technologies.

Ikerian, parent company of RetinAI, secures USD 6.18 million for AI-driven medical advancements

13 May 2024

Testmate Health, a Lausanne-based start-up, has successfully raised USD 6 million to advance the development and commercialization of their at-home rapid test kits for sexually transmitted infections (STIs).

Testmate Health raises USD 6 million to combat STIs with innovative home testing kits

8 May 2024

Bernese medtech machineMD and Oxford-based gaitQ have jointly received a million-dollar research grant from InnovateUK and Innosuisse, aimed at enhancing the monitoring and early detection of Parkinson's disease.

machineMD and gaitQ awarded grant for Parkinson’s research in the UK and Switzerland

7 May 2024

EP Equity Investment (EPEI), a company dedicated to investing in promising European companies, has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.

Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment

6 May 2024

Takeda Pharmaceutical has announced a CHF 5 million investment in renewable energy for its Neuchâtel facility.

Takeda commits CHF 5 million to renewable energy for its Neuchâtel site

29 April 2024

Risklick, a spin-off from the University of Bern, has unveiled its cutting-edge software, Protocol AI, designed to transform the landscape of pharmaceutical development.

UniBe spin-off Risklick unveils AI tool to streamline clinical trials

29 April 2024

Researchers at the EPFL have engineered lab-grown mini-colons that replicate the development of colorectal tumors with high fidelity.

EPFL scientists create lab-grown mini-colons to advance colorectal cancer research

29 April 2024

1 2 3 4 5 6 7 8 … 35